Tasly Biopharma of Shanghai has filed a prospectus for a Hong Kong IPO. The transaction, which has been expected for the past year, could raise as much as $1 billion. Tasly Bio is the biologics arm of Tasly Pharma, a TCM company that decided in...
Read moreMicroPort Orthopedics, a US division of Shanghai’s medical device maker, MicroPort Scientific, launched the Evolution® NitrX™ Medial-Pivot Knee System, the latest version of its knee replacement product. The newest NitrX™ product features a...
Read moreChina’s Amoy Diagnostics will partner with Loxo Oncology, a developer of targeted cancer drugs owned by Eli Lilly and Company, to supply it with accompanying reagents for genetic diagnosis during clinical trials of new drugs in Asia. The...
Read moreTerns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...
Read moreEmployer medical costs are projected to rise by 6% next year, according to PwC. The rate of increase is a four-year high, due in part to rising drug prices. The jump is attributed to expensive specialty drugs that weren’t available a few years...
Read moreJanssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California...
Read moredMed Biopharma, a Shanghai clinical CRO, has opened a Washington office to help China biopharmas complete their US regulatory filings. Since 2017, China’s harmonization with the regulatory systems of other countries revolutionized the...
Read moreGilead Sciences and Nurix, based in Forest City, Calif. and San Francisco, respectively, signed a global strategic collaboration deal that could hit $2.48 billion. The focus will be on discovering drugs that use the body’s natural protein control...
Read moreCellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell...
Read moreCARsgen Therapeutics, a Shanghai CAR-T company, was approved to start US trials of its fully human BCMA (B-Cell Maturation Antigen)-CAR-T therapy for patients with relapsed/refractory multiple myeloma. Four months ago, China’s NMPA approved...
Read moreBeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks...
Read moreCASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...
Read more
